Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase NA 2Phase 2 2Phase 1/2 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 399Carboplatin 307Gemcitabine 287Nivolumab 276Paclitaxel 274Cisplatin 253Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 196Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × ferumoxtran-10 × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
384 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡